COMPLETE REMISSION RATE， CRR

Clinical trials for COMPLETE REMISSION RATE， CRR explained in plain language.

Never miss a new study

Get alerted when new COMPLETE REMISSION RATE， CRR trials appear

Sign up with your email to follow new studies for COMPLETE REMISSION RATE， CRR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

Promising new combo tackles rare blood cancer

Disease control Not yet recruiting

This study tests a new three-drug combination (sintilimab, chidamide, and azacitidine) as the first treatment for people with early-stage extranodal NK/T-cell lymphoma, a rare blood cancer. About 30 participants will receive the drugs, and depending on how well the cancer respond…

Matched conditions: COMPLETE REMISSION RATE， CRR

Phase: NA • Sponsor: Sun Yat-sen University • Aim: Disease control

Last updated Apr 26, 2026 19:37 UTC

COMPLETE REMISSION RATE， CRR

Get alerted when new COMPLETE REMISSION RATE， CRR trials appear

Promising new combo tackles rare blood cancer